Norifaz Trio (Colecalciferol, Calcium Carbonate | Risedronate Sodium)

Colecalciferol/Calcium carbonate/Risedronate sodium, the active ingredient in Norifaz Trio, is a bisphosphonate, calcium supplement and vitamin D supplement presented as an oral tablet for oral use. It is used to treat osteoporosis and to reduce fracture risk in adults at risk of bone loss.

GNH USA supplies Norifaz Trio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norifaz Trio, a combination bisphosphonate, calcium and vitamin D product, is indicated for conditions involving bone loss.

- Osteoporosis: reduces the risk of vertebral and non‑vertebral fractures. - Prevention of bone loss: helps maintain bone mineral density in post‑menopausal women. - Fracture risk reduction: lowers the incidence of fragility fractures in patients with low bone mass.

Common side effects are generally mild and affect the gastrointestinal tract.

Common Side Effects: - Nausea: mild stomach upset. - Abdominal pain: discomfort in the abdomen. - Constipation: difficulty passing stools. - Dyspepsia: indigestion or heartburn.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: exposed bone in the jaw area. - Atypical femur fracture: unusual break in the thigh bone. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Acute renal impairment: sudden decrease in kidney function.

Before initiating therapy, clinicians should assess several safety factors.

- Renal function: evaluate kidney status and adjust use if impaired. - Gastrointestinal disorders: monitor for esophageal irritation or ulceration. - Calcium intake: ensure adequate dietary calcium to support supplementation. - Vitamin D status: correct deficiency before starting treatment. - Concomitant medications: avoid taking oral calcium or iron supplements within two hours of the dose. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Norifaz Trio may interact with other medicines that affect bone or mineral metabolism.

Major Interactions (Avoid): - Other bisphosphonates: concurrent use can increase toxicity. - Simultaneous oral calcium, iron, or antacids within 2 hours: markedly reduces risedronate absorption. - NSAIDs: increase risk of gastrointestinal irritation. - Severe renal impairment: contraindicated due to reduced clearance.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly affect absorption. - Glucocorticoids: can diminish bone‑protective effect. - Loop or thiazide diuretics: may alter calcium balance.